Synthetic Biologics, Inc. (SYN) Short Interest Update

Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) saw a significant drop in short interest in November. As of November 30th, there was short interest totalling 5,632,047 shares, a drop of 10.2% from the November 15th total of 6,268,579 shares. Based on an average daily volume of 710,788 shares, the days-to-cover ratio is currently 7.9 days. Currently, 4.9% of the company’s stock are short sold.

A number of analysts have weighed in on the stock. BidaskClub cut shares of Synthetic Biologics from a “hold” rating to a “sell” rating in a report on Saturday, November 4th. Zacks Investment Research cut shares of Synthetic Biologics from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Finally, ValuEngine cut shares of Synthetic Biologics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $3.92.

Synthetic Biologics (NYSEAMERICAN:SYN) opened at $0.54 on Friday. Synthetic Biologics has a 1-year low of $0.41 and a 1-year high of $1.05.

Synthetic Biologics (NYSEAMERICAN:SYN) last announced its earnings results on Wednesday, November 1st. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.10).

TRADEMARK VIOLATION WARNING: This piece was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at

About Synthetic Biologics

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

What are top analysts saying about Synthetic Biologics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Synthetic Biologics and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit